What Duchesnay does

Duchesnay Inc. is a Canadian specialty pharmaceutical company headquartered in Blainville, Quebec, that develops and commercializes prescription pharmaceutical products and medical devices primarily for women's health across pregnancy, contraception, menopause, urology, and bacterial vaginosis. Founded in 1970 and re-oriented toward women's health in 1992 following a family member's difficult pregnancy, it became the first pharmaceutical company in Canada dedicated specifically to that therapeutic area. Its portfolio spans proprietary formulations including delayed-release tablets (Diclectin for nausea and vomiting of pregnancy), modified-release capsules (Mictoryl for urology), the novel PrRingza year-long reusable contraceptive vaginal ring co-developed with the Population Council, and oral contraceptives (Slynd), all manufactured at a Quebec facility that has tripled capacity since 2021.

The company operates as part of Duchesnay Pharmaceutical Group, a six-company private structure that also includes Duchesnay USA, Medunik Canada/USA (rare diseases), and Analog Pharma Canada (affordable generics, founded January 2024). Duchesnay distributes primarily through Canadian pharmacies reimbursed via public drug plans and private insurance, deploys field sales representatives targeting OB/GYNs and primary care prescribers, runs a toll-free medical information service, and exports to more than 50 countries. Following a June 2021 management buyout, the Group has doubled its workforce, expanded exports tenfold, launched new products including PrALOG and PrRingza, signed a license with Mochida Pharmaceutical for the Japanese market, and been selected for the Government of Canada's Global Hypergrowth Project.

Name

Duchesnay

Legal name

Duchesnay Inc.

Website

https://duchesnay.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

51–100 employees

Short description

Duchesnay is a Canadian specialty pharmaceutical company developing and manufacturing prescription drugs and medical devices for women's health across pregnancy, contraception, menopause, urology, and bacterial vaginosis, serving Canadian patients and exporting to over 50 countries.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmacies and Drug Retailers (45611)

SIC

Pharmaceutical Preparations (2834), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

akta.pro secondary industries

Medical Cannabis Dispensaries (CRANAFAB), CBD/Hemp Wellness & Supplements Retail (CRANAHAC), Compounding & Customized Medication Management Support (HSABALAL)

Keywords

• Women's health pharmaceuticals
• Specialty prescription drugs
• Prenatal care medications
• Contraceptive pharmaceutical products
• Menopause therapeutics

Headquarters

HQ city

Blainville

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Prescription Pharmaceutical Products: Duchesnay generates revenue primarily through the sale of prescription pharmaceutical products in Canada, including Diclectin® for nausea and vomiting of pregnancy, Osphena® for menopause symptoms, Slynd® for contraception, Mictoryl® for urology, and other therapeutic products. Revenue flows through pharmacy dispensaries reimbursed by public drug plans and private insurance.
2. Generic Medications (Analog Pharma Canada): Through its subsidiary Analog Pharma Canada (founded January 2024), Duchesnay sells affordable generic versions of its own branded drugs, including PrALOG-Doxylamine/Pyridoxine™ as a generic of PrDiclectin®, diversifying revenue into the generic pharmaceutical market.
3. International Licensing and Partnerships: Duchesnay generates revenue through licensing agreements for its proprietary products in international markets, such as the partnership with Mochida Pharmaceutical Co., Ltd. to bring Bonjesta® to Japan, with anticipated product launch by 2030.
4. Manufacturing and Export: With a state-of-the-art manufacturing plant in Quebec, Duchesnay exports pharmaceutical products to more than 50 countries, representing significant international revenue generation.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Duchesnay is a Canadian specialty pharmaceutical company that develops, manufactures, and distributes prescription medications and medical devices primarily for women's health across the full life continuum, from pregnancy through menopause. Its portfolio covers nausea and vomiting of pregnancy, contraception, dyspareunia, bacterial vaginosis, overactive bladder, prenatal nutrition, and proctology. Products are manufactured domestically in Quebec and distributed through Canadian pharmacies with reimbursement from public and private drug plans, while international expansion is delivered through licensing partnerships and exports to more than 50 countries.

Product overview

Duchesnay is a Canadian specialty pharmaceutical company that offers a portfolio of prescription pharmaceutical products and medical devices for women's health and related therapeutic areas. The product portfolio spans obstetrics and gynecology (Diclectin®, Osphena®), contraception (Ringza™, Slynd®), proctology (Proctofoam-HC®), urology (Mictoryl® product line), vitamin-mineral supplements for prenatal/postpartum use (PregVit®, Pregvit folic 5®), and bacterial vaginosis treatment (Vablys®). The company also manufactures generic medications through its subsidiary Analog Pharma Canada. Products are manufactured primarily in Canada with some imported ingredients, and certain products carry Kosher-Halal certifications.

Differentiator

Problem solved

Functional benefit

Brands

• Diclectin: Doxylamine succinate (10 mg) pyridoxine hydrochloride (10 mg) delayed release tablet for nausea and vomiting of pregnancy
• PregVit
• Pregvit folic 5
• Mictoryl
• Osphena
• Ringza
• Slynd
• Vablys
• Proctofoam-HC
• Prevegyne

Products and services

• Diclectin® Doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) delayed-release tablet indicated for nausea and vomiting of pregnancy. Kosher-Halal certified and manufactured in Canada. Distributed through Canadian pharmacies and reimbursed through public and private drug plans.
• Osphena® Ospemifene tablets 60 mg indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. Targeted at postmenopausal women and prescribed by OB/GYNs and primary care physicians.
• Slynd® Drospirenone tablets 4 mg, a progestin-only oral contraceptive pill indicated for contraception in women. Targeted at women seeking estrogen-free contraception and prescribed by OB/GYNs and primary care physicians.
• Ringza™ (PrRingza™) Segesterone acetate and ethinylestradiol vaginal system delivering 0.15 mg segesterone acetate and 0.013 mg ethinylestradiol per day. A reusable silicone ring providing up to one year of contraception. Co-developed with the Population Council; Canada was the first country to introduce this product globally.
• Mictoryl® Pediatric 5 mg Propiverine hydrochloride tablets 5 mg for pediatric urology conditions, including overactive bladder. Prescribed by urologists and primary care physicians.
• Mictoryl® 30 mg Propiverine hydrochloride modified-release capsules 30 mg for urology indications including overactive bladder. Prescribed by urologists.
• Mictoryl® 45 mg Propiverine hydrochloride modified-release capsules 45 mg for urology indications including overactive bladder. Prescribed by urologists.
• PregVit® Vitamin-mineral supplement tablets for prenatal and postpartum use. Kosher-Halal certified and manufactured in Canada. Used by pregnant and breastfeeding women for nutritional support.
• Pregvit folic 5® Vitamin-mineral supplement tablets with high-dose folic acid (5 mg) for prenatal use. Kosher-Halal certified and manufactured in Canada. Indicated for women requiring elevated folic acid intake during pregnancy.
• Proctofoam-HC® Hydrocortisone acetate and pramoxine hydrochloride aerosol foam for proctology indications. Used for the symptomatic relief of anorectal disorders and prescribed by primary care physicians and colorectal specialists. Currently experiencing drug shortage per source data.
• Prevegyne® Vitamin C (ascorbic acid) 250 mg controlled-release vaginal tablet. Listed in source data as no longer available in Canada.
• Vablys® Dequalinium chloride tablets 10 mg indicated for the treatment of bacterial vaginosis. Prescribed by OB/GYNs and primary care physicians for adult women.
• Bonjesta® Doxylamine succinate and pyridoxine combination product licensed to Mochida Pharmaceutical Co., Ltd. for the Japanese market. Intended to address the lack of approved nausea and vomiting of pregnancy treatments in Japan, with anticipated product launch by 2030.
• PrALOG-Doxylamine/Pyridoxine™ Affordable generic version of PrDiclectin® (doxylamine succinate and pyridoxine) for managing nausea and vomiting of pregnancy, sold through Analog Pharma Canada, a wholly-owned subsidiary of Duchesnay Pharmaceutical Group. First product launched by Analog Pharma Canada in 2025; manufactured in Quebec.

Quantifiable outcome

• Tripled annual tablet production capacity since 2021, enabling greater domestic supply resilience
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered moderate and core.

• PeriPharmmoderateGTM or Marketing Partner · 22 April 2026Duchesnay and PeriPharm jointly published a research article in the Journal of Obstetrics and Gynaecology of Canada revealing significant gaps in women's health medication access in Canada, based on a 20-year analysis (2003–2023). Duchesnay provided financial support for the PeriPharm study, and the findings were presented at the Femtech Canada Forum. The companies are using these findings to advocate for regulatory and reimbursement policy reforms to improve access to innovative therapies for Canadian women.
• Population CouncilcoreStrategic or Co-development Partner · 7 April 2026The Population Council (New York-based) collaborated with Duchesnay to develop PrRingza™, a contraceptive vaginal system releasing segesterone acetate and ethinylestradiol, reusable for up to one year. Duchesnay launched the product in Canada as the first country globally. The Council's scientific expertise in contraceptive development combined with Duchesnay's regulatory and commercial capabilities in women's health made this co-development possible. The partnership was also extended to develop a potential new treatment for multiple sclerosis.
• Mochida Pharmaceutical Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 15 December 2025Duchesnay Inc. and Mochida Pharmaceutical Co., Ltd. signed a license agreement to bring Bonjesta® (doxylamine succinate/pyridoxine) to the Japanese market, addressing the lack of approved treatments for nausea and vomiting of pregnancy in Japan. Mochida will conduct research and seek regulatory approval, with a product launch targeted for 2030. This partnership represents a strategic milestone for Duchesnay's international expansion, as quoted by VP Suzanne Paszkiewicz in Les Affaires.
• Government of Canada (Global Hypergrowth Project)coreOthersDuchesnay Pharmaceutical Group (DPG) was selected as one of only eight companies across Canada for the Government of Canada's Global Hypergrowth Project, receiving exclusive and personalized support for at least two years to accelerate growth into an anchor firm in the Canadian economy. This recognition confers strategic government support and access to growth resources.
• Analog Pharma CanadacoreOthersAnalog Pharma Canada is a pharmaceutical company founded in January 2024 and wholly part of Duchesnay Pharmaceutical Group. It launched its first product — PrALOG-Doxylamine/Pyridoxine™, a generic version of DPG's flagship PrDiclectin® — leveraging the Group's manufacturing capabilities and maternal health expertise. Its mandate is to build a portfolio of high-quality, affordable generic medications targeting orphan drugs and Duchesnay-owned products, supporting a self-sustainable Canadian healthcare supply chain.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Theramex: Global specialty pharmaceutical company focused exclusively on women's health, covering contraception, fertility, menopause, and related therapeutic areas. Directly comparable as a women's-health-only specialty pharma with branded prescription products distributed internationally.
• Exeltis: Specialty pharmaceutical division focused on women's health, maternal health, and reproductive care across multiple geographies. Closely comparable as a women's health specialty pharma leveraging partnerships and licensing to extend global reach.

Broad incumbents

• Organon: Large global women's health-focused pharmaceutical company spun out of Merck, offering prescription therapies across contraception, fertility, and menopause. Comparable as a broader women's health incumbent whose portfolio overlaps Duchesnay's core therapeutic categories.
• Bayer (Women's Health / Pharma): Major pharmaceutical company with a substantial women's health portfolio spanning contraception (Mirena, Yaz), menopause, and gynecological therapies. Comparable as a broad incumbent whose franchise products compete in the same therapy areas where Duchesnay operates.
• Padagis (formerly TherapeuticsMD women's health portfolio): Specialty pharmaceutical company with a significant women's health portfolio in contraception, menopause, and prenatal care in North America. Comparable as a North American-focused women's health branded and generics player.
• AbbVie: Large diversified pharmaceutical company with a women's health portfolio that includes contraception (Lo Loestrin), menopause therapy, and gynecological products. Comparable as a broad incumbent competing in the same prescriber channels.
• Endo International: Specialty pharmaceutical company with branded and generic women's health products, including contraceptives and menopause therapies. Comparable as a North American-focused women's health specialty/generics player with similar product mix.

Emerging players

• Agile Therapeutics: Women's health specialty pharma focused on contraception, with branded hormonal contraceptive products brought to market through partnerships. Comparable as an emerging women's-health specialist pursuing similar regulatory and commercialization pathways.
• Lupin Pharmaceuticals (Women's Health): Global pharmaceutical company with a growing women's health segment including hormonal contraceptives and prenatal supplements. Comparable in product categories such as prenatal vitamins and hormonal contraception, with broader geographic reach.
• Amneal Pharmaceuticals: Specialty and generics pharmaceutical company with women's health offerings including hormonal contraceptives and prenatal supplements. Comparable through its generic/specialty mix and overlap in prenatal and contraceptive categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/duchesnay
• Instagraminstagram.com/slyndcanada
• Xx.com/duchesnay

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Duchesnay